Related Experiment Video
Updated: Mar 30, 2026
06:49
Reduced Itraconazole Concentration and Durations Are Successful in Treating Batrachochytrium dendrobatidis Infection in Amphibians
Published on: March 14, 2014
12.1K
Oral administration and younger age decrease plasma concentrations of voriconazole in pediatric patients
Karin Kato1, Miki Nagao2, Masaki Yamamoto2
1Department of Clinical Laboratory Medicine, Kyoto University Graduate School of Medicine, 54 Shogoin-Kawaharacho, Sakyo-ku, Kyoto, Japan; Department of Anesthesia, Kyoto University Graduate School of Medicine, 54 Shogoin-Kawaharacho, Sakyo-ku, Kyoto, Japan.
Summary
Optimizing voriconazole dosing in children is crucial. Younger children and oral administration require higher doses to prevent poor outcomes in invasive fungal infections.
Area of Science:
- Pharmacology
- Pediatric Medicine
- Infectious Diseases
Background:
- Voriconazole is a critical antifungal medication for invasive fungal infections like aspergillosis.
- Optimizing voriconazole dosage is essential for efficacy and minimizing adverse events.
- Limited data exist on optimal voriconazole dosing in pediatric populations.
Purpose of the Study:
- To analyze voriconazole plasma concentrations in pediatric patients.
- To identify factors influencing voriconazole levels in children.
- To provide evidence-based recommendations for pediatric voriconazole dosing.
Main Methods:
- Retrospective analysis of voriconazole concentrations in patients aged 0-18 years.
- Literature review of published pediatric voriconazole studies.
- Statistical analysis to identify factors associated with voriconazole concentrations and outcomes.
Main Results:
- Younger age and oral voriconazole administration were significantly associated with lower plasma concentrations (P < 0.01).
- Low voriconazole concentrations correlated with unfavorable patient outcomes (P = 0.01).
- Literature suggests higher doses are needed for younger children and oral administration.
Conclusions:
- Current voriconazole dosing may be insufficient for pediatric patients, especially younger ones receiving oral therapy.
- Escalation of both initial and maintenance voriconazole doses is recommended for pediatric patients.
- Further research and therapeutic drug monitoring are vital for optimizing voriconazole treatment in children.
More Related Videos
Related Concept Videos
01:26Pharmacokinetics in Pediatric Patients: Drug Excretion
373
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
373
01:17Pharmacokinetics in Pediatric Patients: Drug Distribution
462
Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
462
01:23Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
712
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
712
01:24Pharmacokinetics in Pediatric Patients: Drug Metabolism
330
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
330
01:29Drug Dosing: Infants and Children
751
Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
751
01:22Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Absorption
809
As individuals age, their body's physiology evolves, affecting drug pharmacokinetics. The most apparent changes occur in the gastrointestinal tract, where an increase in gastric pH, a delay in gastric emptying, and a reduction in gastrointestinal motility are observed. Remarkably, these changes do not substantially modify the absorption of orally administered drugs, particularly those absorbed via passive diffusion.Transdermal drug delivery emerges as a highly viable method for older adults due...
809